Ann: Patrys to License Chinese Rights for PAT-SC1, page-61

If you look at a long term chart of something like NEU (2005-now) you could suggest we are at a similar point they were in about end of 2010.

Easy to think its all over at these points in time.

Reality is significant cash is likely on its way, global pharma has shown interest and with a little cash and time the problems facing production may be able to be solved.

I cant see the Chinese paying for something they see no chance of being able to produce and sell at profit.

A potential partner generated some excellent results with SC-1 and there were a number of parties looking at it.

The corporate deals team at PAB should broker a realistic deal- Suzie Jones has experience here.

Rights are retained for markets other than china also.

PAB initially purchased SC1, I wonder what they paid back then?